Neuroimaging predictors of treatment response in anxiety disorders

Biology of Mood & Anxiety Disorders

Lisa M Shin¹  F Caroline Davis¹  Michael B VanElzakker¹  Mary K Dahlgren¹  Stacey J Dubois¹ 

[1] Department of Psychiatry, Massachusetts General Hospital, Charlestown, MA, USA

关键词: PET;    fMRI;    Orbitofrontal cortex;    Anterior cingulate cortex;    Medial prefrontal cortex;    Amygdala;    Generalized anxiety disorder;    Posttraumatic stress disorder;    Obsessive-compulsive disorder;    Social anxiety disorder;   

Others  :  791884
DOI  :  10.1186/2045-5380-3-15

 received in 2013-04-22, accepted in 2013-06-19,  发布年份 2013

【 摘 要 】

Although several psychological and pharmacological treatment options are available for anxiety disorders, not all patients respond well to each option. Furthermore, given the relatively long duration of adequate treatment trials, finding a good treatment fit can take many months or longer. Thus, both clinicians and patients would benefit from the identification of objective pre-treatment measures that predict which patients will best respond to a given treatment. Recent studies have begun to use biological measures to help predict symptomatic change after treatment in anxiety disorders. In this review, we summarize studies that have used structural and functional neuroimaging measures to predict treatment response in obsessive-compulsive disorder (OCD), posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), and social anxiety disorder (SAD). We note the limitations of the current studies and offer suggestions for future research. Although the literature is currently small, we conclude that pre-treatment neuroimaging measures do appear to predict treatment response in anxiety disorders, and future research will be needed to determine the relative predictive power of neuroimaging measures as compared to clinical and demographic measures.

【 授权许可】

   
2013 Shin et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62(6):593-602.
• [2]Ahola K, Virtanen M, Honkonen T, Isometsa E, Aromaa A, Lonnqvist J: Common mental disorders and subsequent work disability: a population-based Health 2000 Study. J Affect Disord 2011, 134(1–3):365-372.
• [3]Cicek E, Cicek IE, Kayhan F, Uguz F, Kaya N: Quality of life, family burden and associated factors in relatives with obsessive-compulsive disorder. Gen Hosp Psychiatry 2013, 35(3):253-258.
• [4]Wedegaertner F, Arnhold-Kerri S, Sittaro NA, Bleich S, Geyer S, Lee WE: Depression- and anxiety-related sick leave and the risk of permanent disability and mortality in the working population in Germany: a cohort study. BMC Publ Health 2013, 13(1):145. BioMed Central Full Text
• [5]Mancebo MC, Eisen JL, Pinto A, Greenberg BD, Dyck IR, Rasmussen SA: The brown longitudinal obsessive compulsive study: treatments received and patient impressions of improvement. J Clin Psychiatry 2006, 67(11):1713-1720.
• [6]Ipser JC, Stein DJ: Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol 2012, 15(6):825-840.
• [7]Hanrahan F, Field AP, Jones FW, Davey GC: A meta-analysis of cognitive therapy for worry in generalized anxiety disorder. Clin Psychol Rev 2013, 33(1):120-132.
• [8]Hofmann SG, Smits JA: Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008, 69(4):621-632.
• [9]Tolin DF: Is cognitive-behavioral therapy more effective than other therapies? A meta-analytic review. Clin Psychol Rev 2010, 30(6):710-720.
• [10]Tukel R, Bozkurt O, Polat A, Genc A, Atli H: Clinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Psychiatry Clin Neurosci 2006, 60(4):404-409.
• [11]Connor KM, Hidalgo RB, Crockett B, Malik M, Katz RJ, Davidson JR: Predictors of treatment response in patients with posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25(2):337-345.
• [12]Karatzias A, Power K, McGoldrick T, Brown K, Buchanan R, Sharp D, Swanson V: Predicting treatment outcome on three measures for post-traumatic stress disorder. Eur Arch Psychiatry Clin Neurosci 2007, 257(1):40-46.
• [13]Doehrmann O, Ghosh SS, Polli FE, Reynolds GO, Horn F, Keshavan A, Triantafyllou C, Saygin ZM, Whitfield-Gabrieli S, Hofmann SG, et al.: Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry 2013, 70(1):87-97.
• [14]Otto MW, Pollack MH, Gould RA, Worthington JJ 3rd, McArdle ET, Rosenbaum JF: A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord 2000, 14(4):345-358.
• [15]Walkup JT, Labellarte MJ, Riddle MA, Pine D, Greenhill L, Klein R, Davies M, Sweeney M, Fu C, Abikoff H, et al.: Searching for moderators and mediators of pharmacological treatment effects in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003, 42(1):13-21.
• [16]Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L: Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 1999, 156(9):1409-1416.
• [17]Baer L, Jenike MA, Black DW, Treece C, Rosenfeld R, Greist J: Effect of axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1992, 49(11):862-866.
• [18]Chambless DL, Tran GQ, Glass CR: Predictors of response to cognitive-behavioral group therapy for social phobia. J Anxiety Disord 1997, 11(3):221-240.
• [19]Bryant RA, Felmingham K, Kemp A, Das P, Hughes G, Peduto A, Williams L: Amygdala and ventral anterior cingulate activation predicts treatment response to cognitive behaviour therapy for post-traumatic stress disorder. Psychol Med 2008, 38:555-561.
• [20]Bryant RA, Felmingham KL, Falconer EM, Pe Benito L, Dobson-Stone C, Pierce KD, Schofield PR: Preliminary evidence of the short allele of the serotonin transporter gene predicting poor response to cognitive behavior therapy in posttraumatic stress disorder. Biol Psychiatry 2010, 67(12):1217-1219.
• [21]Lee IS, Kim KJ, Kang EH, Yu BH: Beta-adrenoceptor affinity as a biological predictor of treatment response to paroxetine in patients with acute panic disorder. J Affect Disord 2008, 110(1–2):156-160.
• [22]Yehuda R, Bierer LM, Sarapas C, Makotkine I, Andrew R, Seckl JR: Cortisol metabolic predictors of response to psychotherapy for symptoms of PTSD in survivors of the World Trade Center attacks on September 11, 2001. Psychoneuroendocrinology 2009, 34(9):1304-1313.
• [23]Graybiel AM, Rauch SL: Toward a neurobiology of obsessive-compulsive disorder. Neuron 2000, 28(2):343-347.
• [24]Rauch S, Whalen P, Dougherty D, Jenike M: Neurobiological models of obsessive compulsive disorders. In Obsessive-compulsive disorders: practical management. edn. Edited by Jenike M, Baer L, Minichiello W. Boston: Mosby; 1998:222-253.
• [25]Baxter LR Jr, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE: Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987, 44(3):211-218.
• [26]Rauch SL, Jenike MA, Alpert NM, Baer L, Breiter HC, Savage CR, Fischman AJ: Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 1994, 51(1):62-70.
• [27]Rotge JY, Guehl D, Dilharreguy B, Cuny E, Tignol J, Bioulac B, Allard M, Burbaud P, Aouizerate B: Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci 2008, 33(5):405-412.
• [28]Whiteside SP, Port JD, Abramowitz JS: A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res 2004, 132(1):69-79.
• [29]Baxter LR Jr, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, Alazraki A, Selin CE, Ferng HK, Munford P, et al.: Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992, 49(9):681-689.
• [30]Saxena S, Gorbis E, O’Neill J, Baker SK, Mandelkern MA, Maidment KM, Chang S, Salamon N, Brody AL, Schwartz JM, et al.: Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder. Mol Psychiatry 2009, 14(2):197-205.
• [31]Schwartz JM, Stoessel PW, Baxter LR Jr, Martin KM, Phelps ME: Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1996, 53(2):109-113.
• [32]Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A, Friedland R, Rapoport SI, Rapoport JL: Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry 1989, 46(6):518-523.
• [33]Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, Phelps ME, Baxter LR Jr: Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 1999, 21(6):683-693.
• [34]Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR Jr: Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry 2003, 160(3):522-532.
• [35]Hendler T, Goshen E, Tzila Zwas S, Sasson Y, Gal G, Zohar J: Brain reactivity to specific symptom provocation indicates prospective therapeutic outcome in OCD. Psychiatry Res 2003, 124(2):87-103.
• [36]Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA: Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 2002, 27(5):782-791.
• [37]Sanematsu H, Nakao T, Yoshiura T, Nabeyama M, Togao O, Tomita M, Masuda Y, Nakatani E, Nakagawa A, Kanba S: Predictors of treatment response to fluvoxamine in obsessive-compulsive disorder: an fMRI study. J Psychiatr Res 2010, 44(4):193-200.
• [38]Ho Pian KL, van Megen HJ, Ramsey NF, Mandl R, van Rijk PP, Wynne HJ, Westenberg HG: Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res 2005, 138(2):89-97.
• [39]Buchsbaum MS, Hollander E, Pallanti S, Baldini Rossi N, Platholi J, Newmark R, Bloom R, Sood E: Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology 2006, 53(3):157-168.
• [40]Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, Baxter LR Jr: FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res 1998, 84(1):1-6.
• [41]Hoexter MQ, Dougherty DD, Shavitt RG, D'Alcante CC, Duran FL, Lopes AC, Diniz JB, Batistuzzo MC, Evans KC, Bressan RA, et al.: Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive-compulsive disorder. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 2013, 23(7):569-580.
• [42]Milad MR, Quinn BT, Pitman RK, Orr SP, Fischl B, Rauch SL: Thickness of ventromedial prefrontal cortex in humans is correlated with extinction memory. Proc Natl Acad Sci USA 2005, 102(30):10706-10711.
• [43]Milad MR, Wright CI, Orr SP, Pitman RK, Quirk GJ, Rauch SL: Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Biol Psychiatry 2007, 62(5):446-454.
• [44]Rauch SL, Dougherty DD, Cosgrove GR, Cassem EH, Alpert NM, Price BH, Nierenberg AA, Mayberg HS, Baer L, Jenike MA, et al.: Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for obsessive compulsive disorder. Biol Psychiatry 2001, 50(9):659-667.
• [45]Van Laere K, Nuttin B, Gabriels L, Dupont P, Rasmussen S, Greenberg BD, Cosyns P: Metabolic imaging of anterior capsular stimulation in refractory obsessive-compulsive disorder: a key role for the subgenual anterior cingulate and ventral striatum. J Nucl Med 2006, 47(5):740-747.
• [46]Rauch SL, Shin LM, Whalen PJ, Pitman RK: Neuroimaging and the neuroanatomy of PTSD. CNS Spectrums 1998, 3(suppl. 2):30-41.
• [47]Rauch SL, Shin LM, Phelps EA: Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research–past, present, and future. Biol Psychiatry 2006, 60(4):376-382.
• [48]Hayes JP, Hayes SM, Mikedis AM: Quantitative meta-analysis of neural activity in posttraumatic stress disorder. Biol Mood Anxiety Disord 2012, 2(1):9. BioMed Central Full Text
• [49]Etkin A, Wager TD: Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 2007, 164(10):1476-1488.
• [50]Patel R, Spreng RN, Shin LM, Girard TA: Neurocircuitry models of posttraumatic stress disorder and beyond: a meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev 2012, 36(9):2130-2142.
• [51]Shin LM, Liberzon I: The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 2010, 35(1):169-191.
• [52]Morey RA, Gold AL, LaBar KS, Beall SK, Brown VM, Haswell CC, Nasser JD, Wagner HR, McCarthy G: Amygdala volume changes in posttraumatic stress disorder in a large case-controlled veterans group. Arch Gen Psychiatry 2012, 69(11):1169-1178.
• [53]Karl A, Schaefer M, Malta LS, Dorfel D, Rohleder N, Werner A: A meta-analysis of structural brain abnormalities in PTSD. Neurosci Biobehav Rev 2006, 30(7):1004-1031.
• [54]Rauch SL, Shin LM, Segal E, Pitman RK, Carson MA, McMullin K, Whalen PJ, Makris N: Selectively reduced regional cortical volumes in post-traumatic stress disorder. Neuroreport 2003, 14(7):913-916.
• [55]Woodward SH, Kaloupek DG, Streeter CC, Martinez C, Schaer M, Eliez S: Decreased anterior cingulate volume in combat-related PTSD. Biol Psychiatry 2006, 59(7):582-587.
• [56]Armony JL, Corbo V, Clement MH, Brunet A: Amygdala response in patients with acute PTSD to masked and unmasked emotional facial expressions. Am J Psychiatry 2005, 162(10):1961-1963.
• [57]Rauch SL, Whalen PJ, Shin LM, McInerney SC, Macklin ML, Lasko NB, Orr SP, Pitman RK: Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: a functional MRI study. Biol Psychiatry 2000, 47(9):769-776.
• [58]Britton JC, Phan KL, Taylor SF, Fig LM, Liberzon I: Corticolimbic blood flow in posttraumatic stress disorder during script-driven imagery. Biol Psychiatry 2005, 57(8):832-840.
• [59]Kim MJ, Chey J, Chung A, Bae S, Khang H, Ham B, Yoon SJ, Jeong DU, Lyoo IK: Diminished rostral anterior cingulate activity in response to threat-related events in posttraumatic stress disorder. J Psychiatr Res 2008, 42(4):268-277.
• [60]Shin LM, Orr SP, Carson MA, Rauch SL, Macklin ML, Lasko NB, Marzol Peters P, Metzger L, Dougherty DD, Cannistraro PA, et al.: Regional cerebral blood flow in amygdala and medial prefrontal cortex during traumatic imagery in male and female Vietnam veterans with PTSD. Arch Gen Psychiatry 2004, 61(2):168-176.
• [61]Shin LM, Wright CI, Cannistraro PA, Wedig MM, McMullin K, Martis B, Macklin ML, Lasko NB, Cavanagh SR, Krangel TS, et al.: A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. Arch Gen Psychiatry 2005, 62(3):273-281.
• [62]Felmingham K, Kemp A, Williams L, Das P, Hughes G, Peduto A, Bryant R: Changes in anterior cingulate and amygdala after cognitive behavior therapy of posttraumatic stress disorder. Psychol Sci 2007, 18(2):127-129.
• [63]Lansing K, Amen DG, Hanks C, Rudy L: High-resolution brain SPECT imaging and eye movement desensitization and reprocessing in police officers with PTSD. J Neuropsychiatry Clin Neurosci 2005, 17(4):526-532.
• [64]Peres JF, Newberg AB, Mercante JP, Simao M, Albuquerque VE, Peres MJ, Nasello AG: Cerebral blood flow changes during retrieval of traumatic memories before and after psychotherapy: a SPECT study. Psychol Med 2007, 37(10):1481-1491.
• [65]Seedat S, Warwick J, van Heerden B, Hugo C, Zungu-Dirwayi N, Van Kradenburg J, Stein DJ: Single photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor. J Affect Disord 2004, 80(1):45-53.
• [66]Cukor J, Spitalnick J, Difede J, Rizzo A, Rothbaum BO: Emerging treatments for PTSD. Clin Psychol Rev 2009, 29(8):715-726.
• [67]Hembree EA, Foa EB: Posttraumatic stress disorder: psychological factors and psychosocial interventions. J Clin Psychiatry 2000, 61(Suppl 7):33-39.
• [68]Bryant RA, Felmingham K, Whitford TJ, Kemp A, Hughes G, Peduto A, Williams LM: Rostral anterior cingulate volume predicts treatment response to cognitive-behavioural therapy for posttraumatic stress disorder. J Psychiatry Neurosci 2008, 33(2):142-146.
• [69]Nardo D, Hogberg G, Looi JC, Larsson S, Hallstrom T, Pagani M: Gray matter density in limbic and paralimbic cortices is associated with trauma load and EMDR outcome in PTSD patients. J Psychiatr Res 2010, 44(7):477-485.
• [70]Krain AL, Gotimer K, Hefton S, Ernst M, Castellanos FX, Pine DS, Milham MP: A functional magnetic resonance imaging investigation of uncertainty in adolescents with anxiety disorders. Biol Psychiatry 2008, 63(6):563-568.
• [71]McClure EB, Monk CS, Nelson EE, Parrish JM, Adler A, Blair RJ, Fromm S, Charney DS, Leibenluft E, Ernst M, et al.: Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. Arch Gen Psychiatry 2007, 64(1):97-106.
• [72]Monk CS, Telzer EH, Mogg K, Bradley BP, Mai X, Louro HM, Chen G, McClure-Tone EB, Ernst M, Pine DS: Amygdala and ventrolateral prefrontal cortex activation to masked angry faces in children and adolescents with generalized anxiety disorder. Arch Gen Psychiatry 2008, 65(5):568-576.
• [73]Nitschke JB, Sarinopoulos I, Oathes DJ, Johnstone T, Whalen PJ, Davidson RJ, Kalin NH: Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. Am J Psychiatry 2009, 166(3):302-310.
• [74]Blair K, Shaywitz J, Smith BW, Rhodes R, Geraci M, Jones M, McCaffrey D, Vythilingam M, Finger E, Mondillo K, et al.: Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry 2008, 165(9):1193-1202.
• [75]Whalen PJ, Johnstone T, Somerville LH, Nitschke JB, Polis S, Alexander AL, Davidson RJ, Kalin NH: A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Biol Psychiatry 2008, 63(9):858-863.
• [76]McClure EB, Adler A, Monk CS, Cameron J, Smith S, Nelson EE, Leibenluft E, Ernst M, Pine DS: fMRI predictors of treatment outcome in pediatric anxiety disorders. Psychopharmacology (Berl) 2007, 191(1):97-105.
• [77]Phan KL, Fitzgerald DA, Nathan PJ, Tancer ME: Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia. Biol Psychiatry 2006, 59(5):424-429.
• [78]Stein MB, Goldin PR, Sareen J, Zorrilla LT, Brown GG: Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch Gen Psychiatry 2002, 59(11):1027-1034.
• [79]Tillfors M, Furmark T, Marteinsdottir I, Fredrikson M: Cerebral blood flow during anticipation of public speaking in social phobia: a PET study. Biol Psychiatry 2002, 52(11):1113-1119.
• [80]Evans KC, Wright CI, Wedig MM, Gold AL, Pollack MH, Rauch SL: A functional MRI study of amygdala responses to angry schematic faces in social anxiety disorder. Depress Anxiety 2008, 25(6):496-505.
• [81]Guyer AE, Lau JY, McClure-Tone EB, Parrish J, Shiffrin ND, Reynolds RC, Chen G, Blair RJ, Leibenluft E, Fox NA, et al.: Amygdala and ventrolateral prefrontal cortex function during anticipated peer evaluation in pediatric social anxiety. Arch Gen Psychiatry 2008, 65(11):1303-1312.
• [82]Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B, Fredrikson M: Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 2002, 59(5):425-433.
• [83]Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergstrom M, et al.: Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 2005, 58(2):132-142.
• [84]Amir N, Klumpp H, Elias J, Bedwell JS, Yanasak N, Miller LS: Increased activation of the anterior cingulate cortex during processing of disgust faces in individuals with social phobia. Biol Psychiatry 2005, 57(9):975-981.
• [85]Lorberbaum JP, Kose S, Johnson MR, Arana GW, Sullivan LK, Hamner MB, Ballenger JC, Lydiard RB, Brodrick PS, Bohning DE, et al.: Neural correlates of speech anticipatory anxiety in generalized social phobia. Neuroreport 2004, 15(18):2701-2705.
• [86]Straube T, Kolassa IT, Glauer M, Mentzel HJ, Miltner WH: Effect of task conditions on brain responses to threatening faces in social phobics: an event-related functional magnetic resonance imaging study. Biol Psychiatry 2004, 56(12):921-930.
• [87]Evans KC, Simon NM, Dougherty DD, Hoge EA, Worthington JJ, Chow C, Kaufman RE, Gold AL, Fischman AJ, Pollack MH, et al.: A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder. Neuropsychopharmacology 2009, 34(2):390-398.
• [88]Fu CH, Steiner H, Costafreda SG: Predictive neural biomarkers of clinical response in depression: A meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis 2013, 52:75-83.
• [89]Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, Silva JA, McGinnis S, Glass TG, Martin CC, et al.: Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997, 8(4):1057-1061.
• [90]Keane TM, Kolb LC, Kaloupek DG, Orr SP, Blanchard EB, Thomas RG, Hsieh FY, Lavori PW: Utility of psychophysiological measurement in the diagnosis of posttraumatic stress disorder: results from a Department of Veterans Affairs Cooperative Study. J Consult Clin Psychol 1998, 66(6):914-923.
• [91]Siegle GJ, Thompson WK, Collier A, Berman SR, Feldmiller J, Thase ME, Friedman ES: Toward clinically useful neuroimaging in depression treatment: prognostic utility of subgenual cingulate activity for determining depression outcome in cognitive therapy across studies, scanners, and patient characteristics. Arch Gen Psychiatry 2012, 69(9):913-924.
• [92]Gong Q, Li L, Tognin S, Wu Q, Pettersson-Yeo W, Lui S, Huang X, Marquand AF, Mechelli A: Using structural neuroanatomy to identify trauma survivors with and without post-traumatic stress disorder at the individual level. Psychol Med 2013, 1-9. epub ahead of print
• [93]Pettersson-Yeo W, Benetti S, Marquand AF, Dell’acqua F, Williams SC, Allen P, Prata D, McGuire P, Mechelli A: Using genetic, cognitive and multi-modal neuroimaging data to identify ultra-high-risk and first-episode psychosis at the individual level. Psychol Med 2013, 1-16. epub ahead of print
• [94]Tang Y, Jiang W, Liao J, Wang W, Luo A: Identifying individuals with antisocial personality disorder using resting-state FMRI. PLoS One 2013, 8(4):e60652.
• [95]Zeng LL, Shen H, Liu L, Hu D: Unsupervised classification of major depression using functional connectivity MRI. Hum Brain Mapp 2013. epub ahead of print